The steps required for successful market access.
Interview with Pfenex explores biosimilars in USA
This year’s event will continue to lead.
Roche’s Erivedge is latest cancer drug to fall foul of NICE number-crunching.
Brexit is already forcing parts of the medical device sector to leave the UK – will pharma have to follow?
Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
The factors shaping the healthcare landscape in emerging markets.